Codexis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. on February 3, 2021, reporting events that occurred on February 2, 2021. The filing addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director appointments and compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size from nine to ten members.
- New Appointment: Esther Martinborough, Ph.D., was appointed as a Class II director, with a term expiring at the 2021 annual meeting of stockholders.
- Independence: The Board determined Dr. Martinborough is independent under Nasdaq Listing Rule 5605.
Compensation and Governance Details
Dr. Martinborough's compensation includes:
- Cash Retainer: $50,000 annually for Board service, plus additional retainers for committee service (committees not yet assigned).
- Initial Equity Grant: A grant of restricted common stock valued at $200,000 (7,262 shares) under the 2019 Incentive Award Plan. Vesting occurs in three equal tranches on each anniversary of the grant date.
- Annual Equity Grant: Future grants of restricted common stock valued at $100,000 following each annual meeting, vesting on the earlier of the first anniversary or the next annual meeting.
- Indemnification: The Company expects to enter into a standard indemnification agreement with Dr. Martinborough.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 7,262 new restricted shares on dilution.
- Confirm the specific committee assignments for Dr. Martinborough once determined.
- Review the Company's 2019 Incentive Award Plan for full vesting conditions and forfeiture clauses.
- Check subsequent filings for the formal execution of the indemnification agreement.